Search research articles
Contact Us
Filters
Showing results (11-20 of 22) with videos related to
Page
of 3
Sort By:
International Psychogeriatrics
|
February 17, 2018
Dementia clinical trial implications of mild behavioral impairment
Moyra E Mortby, Sandra E Black, Serge Gauthier, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry
|
October 20, 2012
Personality factors moderate the associations between apolipoprotein genotype and cognitive function as well as late onset Alzheimer disease
Ilan Dar-Nimrod, Benjamin P Chapman, Peter Franks, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry
|
November 16, 2005
Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial
Pierre N Tariot, Rema Raman, Laura Jakimovich, et al.
Journal of Clinical and Experimental Neuropsychology
|
August 17, 2010
Predicting conversion from mild cognitive impairment to Alzheimer's disease using neuropsychological tests and multivariate methods
Robert M Chapman, Mark Mapstone, John W McCrary, et al.
Trials
|
January 20, 2018
The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial
Roberta W Scherer, Lea Drye, Jacobo Mintzer, et al.
Alzheimer'S Research & Therapy
|
May 24, 2026
Uncovering lipid biomarkers linked to methylphenidate efficacy in treating apathy in Alzheimer's disease: insights from the ADMET 2 trial
Myuri Ruthirakuhan, Maya Mills, Paul Rosenberg, et al.
Archives of General Psychiatry
|
August 4, 2011
Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease
Pierre N Tariot, Lon S Schneider, Jeffrey Cummings, et al.
Drugs
|
September 28, 2025
Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer's Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial
Susan Abushakra, Aidan Power, David Watson, et al.
CNS Drugs
|
December 1, 2025
Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer's Disease: Synthesis of Evidence from Observational and Interventional Trials
Susan Abushakra, P Murali Doraiswamy, John A Hey, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
May 5, 2021
Diagnostic criteria for apathy in neurocognitive disorders
David S Miller, Philippe Robert, Larry Ereshefsky, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 22) with videos related to
Sort By:
Page
of 3
International Psychogeriatrics
|
February 17, 2018
Dementia clinical trial implications of mild behavioral impairment
Moyra E Mortby, Sandra E Black, Serge Gauthier, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry
|
October 20, 2012
Personality factors moderate the associations between apolipoprotein genotype and cognitive function as well as late onset Alzheimer disease
Ilan Dar-Nimrod, Benjamin P Chapman, Peter Franks, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry
|
November 16, 2005
Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial
Pierre N Tariot, Rema Raman, Laura Jakimovich, et al.
Journal of Clinical and Experimental Neuropsychology
|
August 17, 2010
Predicting conversion from mild cognitive impairment to Alzheimer's disease using neuropsychological tests and multivariate methods
Robert M Chapman, Mark Mapstone, John W McCrary, et al.
Trials
|
January 20, 2018
The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial
Roberta W Scherer, Lea Drye, Jacobo Mintzer, et al.
Alzheimer'S Research & Therapy
|
May 24, 2026
Uncovering lipid biomarkers linked to methylphenidate efficacy in treating apathy in Alzheimer's disease: insights from the ADMET 2 trial
Myuri Ruthirakuhan, Maya Mills, Paul Rosenberg, et al.
Archives of General Psychiatry
|
August 4, 2011
Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease
Pierre N Tariot, Lon S Schneider, Jeffrey Cummings, et al.
Drugs
|
September 28, 2025
Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer's Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial
Susan Abushakra, Aidan Power, David Watson, et al.
CNS Drugs
|
December 1, 2025
Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer's Disease: Synthesis of Evidence from Observational and Interventional Trials
Susan Abushakra, P Murali Doraiswamy, John A Hey, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
May 5, 2021
Diagnostic criteria for apathy in neurocognitive disorders
David S Miller, Philippe Robert, Larry Ereshefsky, et al.
Page
of 3